AbbVie is an American publicly traded biopharmaceutical company focused on research, development, and commercialization of advanced medicines. The company was formed as a spin-off from Abbott Laboratories.
AbbVie reported full-year adjusted EPS of $10 and total net revenue of $61.2 billion for 2025. Merit Financial Group raised its fourth-quarter stake in the company to 93,295 shares worth $21.317 million.
AbbVie has received a "Moderate Buy" consensus rating from analysts with an average price target of $253.15. The company reported strong quarterly earnings of $2.71 EPS and $16.62 billion revenue, beating estimates. Recent clinical progress includes positive Phase 1 results for an obesity drug candidate showing 7.8-9.8% weight loss.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
AbbVie announced a quarterly cash dividend of $1.73 per share, payable May 15, 2026. The company has increased its dividend by over 330 percent since 2013 and remains an S&P Dividend Aristocrat.
A single blood test measuring p-tau217 protein can predict when cognitively unimpaired individuals will develop Alzheimer's symptoms, with a margin of error of 3-4 years, potentially accelerating clinical trials.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
The global antibodies market is projected to reach $667.8 billion by 2032 with a 12.9% CAGR, while high throughput antibody production services are expected to grow at 11.2% CAGR through 2033, driven by biopharmaceutical development and monoclonal antibody therapeutics demand.
